For weight loss, only in states that choose to cover it. For sleep apnea, the federal rule points the other way, because tirzepatide under the Zepbound name carries a second, non-weight indication. Which of the two your prescription is written for decides which rule applies. How the brand differs from the diabetes version of the same drug is in Mounjaro vs Zepbound.
Two indications on one label
Zepbound is approved, with diet and exercise, to reduce excess body weight and maintain the loss long term in adults with obesity, or with overweight and at least one weight-related condition[3]. It is also approved to treat moderate to severe obstructive sleep apnea in adults with obesity[3].
The sleep apnea trials enrolled adults with an apnea-hypopnea index of 15 or more events an hour and a body-mass index of 30 or more[3]. The index was measured by polysomnogram, an overnight sleep study[3].
Where the weight-loss exclusion stops
Federal law lets a state exclude “agents when used for anorexia, weight loss, or weight gain”[1]. The words “when used for” tie the exclusion to a use, so it describes a Zepbound prescription for weight and not one for sleep apnea.
A medically accepted indication is any use approved under the Food, Drug, and Cosmetic Act[1]. On a May 2024 call, CMS told state programs that a drug with an excluded use must still be covered for any FDA-approved indication except the excluded one[2]. Its example was Wegovy’s heart indication[2]. CMS did not name Zepbound, but sleep apnea is an FDA-approved indication that is not on the excluded list, so the same rule reaches it.
The weight-loss option was nearly taken away, and was not
A November 2024 proposal would have made obesity drugs used to treat obesity mandatory in Medicaid. The final rule of April 15, 2025 listed that provision among those CMS did not intend to finalize[5]. Weight coverage therefore stays a choice each state makes in its state plan[2].
BALANCE covers one Zepbound presentation
CMS’s BALANCE model negotiates GLP-1 prices and coverage terms for state Medicaid programs that join, with states able to join from May 2026 through January 1, 2027[4]. Its drug list names “the KwikPen formulation of Zepbound”, for weight management as well as existing uses[4]. The vial and the single-dose pen are not on it[4].
Participation is voluntary, patients face qualifications including prior authorization, and CMS says the model will not guarantee coverage for any individual[4]. If your state has joined, the KwikPen is the form to ask about.
| Presentation | BALANCE list | Card with Medicaid | Self-pay, government-insured |
|---|---|---|---|
| Single-dose pen | No | No | No |
| KwikPen (multi-dose, single-patient) | Yes | No | Yes, from $299 a month |
| Single-dose vial | No | No | Yes, from $299 a month |
No published state count covers Zepbound
The one published survey of state Medicaid coverage read preferred drug lists from the first quarter of 2023 and assessed six antiobesity medications: orlistat, lorcaserin, phentermine-topiramate, bupropion-naltrexone, liraglutide and semaglutide[6]. Tirzepatide is not among them, so the survey’s count of 10 of 47 states covering at least one antiobesity medication says nothing about Zepbound[6].
Your state’s own preferred drug list is the only current answer. The same molecule under its diabetes name has its own page, does Medicaid cover Mounjaro, and the semaglutide version of this question is in does Medicaid cover Wegovy.
What to pay if Medicaid will not
The Zepbound savings card requires that you are not enrolled in any state, federal or government-funded healthcare program, and it names Medicaid first[7]. On the same page, the view for government-insured patients offers the KwikPen or the single-dose vial as self-pay, starting at $299 for a month of the 2.5 mg starting dose[7].
Higher doses cost more: $399 at 5 mg and $449 from 7.5 mg up when refilled within 45 days[8]. The full ladder is in Zepbound price, and the refill-window rule is explained in the Zepbound self-pay Journey Program. Compounded tirzepatide sits outside Medicaid altogether; its cash prices are on the tirzepatide price board. The card’s commercial terms, for anyone who leaves Medicaid for a job-based plan, are in Zepbound savings card.